{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:14:13Z","timestamp":1786119253069,"version":"build-2736575974"},"reference-count":65,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,9]]},"DOI":"10.1097\/iae.0b013e3181b1bb1a","type":"journal-article","created":{"date-parts":[[2009,9,2]],"date-time":"2009-09-02T03:15:56Z","timestamp":1251861356000},"page":"1062-1066","source":"Crossref","is-referenced-by-count":85,"title":["ANTI-VEGF DRUGS AS THE 2009 FIRST-LINE THERAPY FOR CHOROIDAL NEOVASCULARIZATION IN PATHOLOGIC MYOPIA"],"prefix":"10.1097","volume":"29","author":[{"given":"SALOMON Y.","family":"COHEN","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-2-20210130","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1016\/S0161-6420(96)30515-0","article-title":"Etiology of choroidal neovascularization in young patients.","volume":"103","author":"Cohen","year":"1996","journal-title":"Ophthalmology"},{"key":"R2-2-20210130","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0002-9394(81)90170-7","article-title":"Pathologic myopia and choroidal neovascularization.","volume":"91","author":"Hotchkiss","year":"1981","journal-title":"Am J Ophthalmol"},{"key":"R3-2-20210130","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/S0161-6420(84)34116-1","article-title":"Natural history of choroidal neovascularization in degenerative myopia.","volume":"91","author":"Avila","year":"1984","journal-title":"Ophthalmology"},{"key":"R4-2-20210130","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1097\/00055735-200106000-00014","article-title":"Natural history of choroidal neovascularization in high myopia.","volume":"12","author":"Miller","year":"2001","journal-title":"Curr Opin Ophthalmol"},{"key":"R5-2-20210130","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1023\/A:1025488429802","article-title":"The natural history of juxtafoveal and subfoveal choroidal neovascularization in high myopia.","volume":"24","author":"Bottoni","year":"2001","journal-title":"Int Ophthalmol"},{"key":"R6-2-20210130","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/S0161-6420(01)01007-7","article-title":"Long-term visual prognosis of choroidal neovascularization in high myopia: a comparison between age groups.","volume":"109","author":"Yoshida","year":"2002","journal-title":"Ophthalmology"},{"key":"R7-2-20210130","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/S0161-6420(03)00461-5","article-title":"Myopic choroidal neovascularization: a 10-year follow-up.","volume":"110","author":"Yoshida","year":"2003","journal-title":"Ophthalmology"},{"key":"R8-2-20210130","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/01.icu.0000120709.35941.e9","article-title":"Myopic choroidal neovascularization: natural course and treatment.","volume":"15","author":"Ohno-Matsui","year":"2004","journal-title":"Curr Opin Ophthalmol"},{"key":"R9-2-20210130","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/S0161-6420(02)01998-X","article-title":"Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial\u2014VIP report no. 3.","volume":"110","author":"Blinder","year":"2003","journal-title":"Ophthalmology"},{"key":"R10-2-20210130","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1136\/bjo.2005.074716","article-title":"Choroidal neovascularisation in pathological myopia: an update in management.","volume":"89","author":"Chan","year":"2005","journal-title":"Br J Ophthalmol"},{"key":"R11-2-20210130","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.survophthal.2007.12.004","article-title":"Choroidal neovascularization in pathologic myopia: recent developments in diagnosis and treatment.","volume":"53","author":"Soubrane","year":"2008","journal-title":"Surv Ophthalmol"},{"key":"R12-2-20210130","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1080\/08820530490520013","article-title":"Two-year results of macular translocation with scleral infolding in myopic choroidal neovascularisation.","volume":"19","author":"Mateo","year":"2004","journal-title":"Semin Ophthalmol"},{"key":"R13-2-20210130","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ajo.2006.09.041","article-title":"Photodynamic therapy vs limited macular translocation in the management of subfoveal choroidal neovascularization in pathologic myopia: a two-year study.","volume":"143","author":"Glacet-Bernard","year":"2007","journal-title":"Am J Ophthalmol"},{"key":"R14-2-20210130","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1001\/archopht.118.3.344","article-title":"Subretinal surgery for choroidal neovascularization in patients with high myopia.","volume":"118","author":"Uemura","year":"2000","journal-title":"Arch Ophthalmol"},{"key":"R15-2-20210130","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1136\/bjo.85.9.1041","article-title":"Surgical removal of subfoveal choroidal neovascularisation in highly myopic patients.","volume":"85","author":"Ruiz-Moreno","year":"2001","journal-title":"Br J Ophthalmol"},{"key":"R16-2-20210130","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1136\/bjo.2005.089458","article-title":"Two-year results of surgical removal of choroidal neovascular membranes related to non-age-related macular degeneration.","volume":"91","author":"Essex","year":"2007","journal-title":"Br J Ophthalmol"},{"key":"R17-2-20210130","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1136\/bjo.84.7.761","article-title":"Radiotherapy for subfoveal neovascularisation associated with pathological myopia: a pilot study.","volume":"84","author":"Kobayashi","year":"2000","journal-title":"Br J Ophthalmol"},{"key":"R18-2-20210130","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/S0002-9394(02)02257-2","article-title":"Selective occlusion of subfoveal choroidal neovascularization in pathologic myopia using a new technique of ingrowth site treatment.","volume":"135","author":"Costa","year":"2003","journal-title":"Am J Ophthalmol"},{"key":"R19-2-20210130","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s10792-006-9010-0","article-title":"Transpupillary thermotherapy for myopic choroidal neovascularization: 1-year follow-up: TTT for myopic CNV.","volume":"26","author":"Ozdek","year":"2005","journal-title":"Int Ophthalmol"},{"key":"R20-2-20210130","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/j.1442-9071.2008.01783.x","article-title":"Subthreshold transpupillary thermotherapy in Chinese patients with myopic choroidal neovascularization: one- and two-year follow up.","volume":"36","author":"Wu","year":"2008","journal-title":"Clin Experiment Ophthalmol"},{"key":"R21-2-20210130","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1111\/j.1600-0420.2005.00506.x","article-title":"Photodynamic therapy in combination with intravitreal triamcinolone for myopic choroidal neovascularization.","volume":"83","author":"Degenring","year":"2005","journal-title":"Acta Ophthalmol Scand"},{"key":"R22-2-20210130","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.ajo.2006.03.003","article-title":"Combined photodynamic therapy and intravitreal triamcinolone acetonide for the treatment of myopic subfoveal choroidal neovascularization.","volume":"142","author":"Marticorena","year":"2006","journal-title":"Am J Ophthalmol"},{"key":"R23-2-20210130","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1136\/bjo.2006.103606","article-title":"Combined photodynamic therapy and intravitreal triamcinolone injection for the treatment of choroidal neovascularisation secondary to pathological myopia: a pilot study.","volume":"91","author":"Chan","year":"2007","journal-title":"Br J Ophthalmol"},{"key":"R24-2-20210130","first-page":"269","article-title":"R\u00e9sultats de la photocoagulation des n\u00e9ovaisseaux sous-r\u00e9tiniens de la myopie forte.","volume":"86","author":"Soubrane","year":"1986","journal-title":"Bull Soc Ophtalmol Fr"},{"key":"R25-2-20210130","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1177\/112067219700700401","article-title":"Long-term visual outcome of choroidal neovascularization in pathologic myopia: natural history and laser treatment.","volume":"7","author":"Secr\u00e9tan","year":"1997","journal-title":"Eur J Ophthalmol"},{"key":"R26-2-20210130","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1097\/00006982-199010000-00002","article-title":"Photocoagulation scar expansion after laser therapy for choroidal neovascularization in degenerative myopia.","volume":"10","author":"Brancato","year":"1990","journal-title":"Retina"},{"key":"R28-2-20210130","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1177\/112067210201200207","article-title":"Long-term visual acuity after argon green laser photocoagulation of juxtafoveal choroidal neovascularization in highly myopic eyes.","volume":"12","author":"Ruiz-Moreno","year":"2002","journal-title":"Eur J Ophthalmol"},{"key":"R29-2-20210130","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1136\/bjo.2004.041624","article-title":"Photodynamic therapy with verteporfin for subfoveal choroidal neovascularisation of pathologic myopia in Chinese eyes: a prospective series of 1 and 2 year follow up.","volume":"88","author":"Lam","year":"2004","journal-title":"Br J Ophthalmol"},{"key":"R30-2-20210130","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1007\/s00417-005-1147-4","article-title":"Quantitative assessment of the long-term effect of photodynamic therapy in patients with pathologic myopia.","volume":"243","author":"Schnurrbusch","year":"2005","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R31-2-20210130","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1097\/01.iae.0000244256.60524.c0","article-title":"Photodynamic therapy with verteporfin for subfoveal choroidal neovascularization secondary to pathologic myopia: long-term study.","volume":"26","author":"Pece","year":"2006","journal-title":"Retina"},{"key":"R32-2-20210130","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1097\/IAE.0b013e31804b1e6f","article-title":"Photodynamic therapy for Taiwanese patients with pathologic myopia: a 2-year follow-up.","volume":"27","author":"Chen","year":"2007","journal-title":"Retina"},{"key":"R33-2-20210130","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1136\/bjo.2007.132795","article-title":"Photodynamic therapy to treat choroidal neovascularisation in highly myopic patients: 4 years\u2019 outcome.","volume":"92","author":"Ruiz-Moreno","year":"2008","journal-title":"Br J Ophthalmol"},{"key":"R34-2-20210130","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/S0002-9394(03)00201-0","article-title":"Photodynamic therapy for juxtafoveal choroidal neovascularization in myopic eyes.","volume":"136","author":"Cohen","year":"2003","journal-title":"Am J Ophthalmol"},{"key":"R35-2-20210130","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1038\/sj.eye.6701681","article-title":"Photodynamic therapy with verteporfin for juxtafoveal choroidal neovascularization secondary to pathologic myopia-1-year results of a prospective series.","volume":"19","author":"Lam","year":"2005","journal-title":"Eye"},{"key":"R36-2-20210130","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1038\/sj.eye.6701680","article-title":"Photodynamic therapy with verteporfin for juxtafoveal choroidal neovascularization secondary to pathological myopia.","volume":"19","author":"Gibson","year":"2005","journal-title":"Eye"},{"key":"R37-2-20210130","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.ajo.2006.11.037","article-title":"Photodynamic therapy with verteporfin for juxtafoveal choroidal neovascularization in pathologic myopia: a long-term follow-up study.","volume":"143","author":"Pece","year":"2007","journal-title":"Am J Ophthalmol"},{"key":"R38-2-20210130","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ajo.2006.09.052","article-title":"Photodynamic therapy for nonsubfoveal choroidal neovascularization in 100 eyes with pathologic myopia.","volume":"143","author":"Virgili","year":"2007","journal-title":"Am J Ophthalmol"},{"key":"R39-2-20210130","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1007\/s00417-004-0949-0","article-title":"Verteporfin photodynamic therapy for extrafoveal choroidal neovascularisation in pathologic myopia.","volume":"242","author":"Gelisken","year":"2004","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R40-2-20210130","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1056\/NEJMoa062655","article-title":"Ranibizumab versus verteporfin for neovascular age-related macular degeneration.","volume":"355","author":"Brown","year":"2006","journal-title":"N Engl J Med"},{"key":"R41-2-20210130","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa054481","article-title":"Ranibizumab for neovascular age-related macular degeneration.","volume":"355","author":"Rosenfeld","year":"2006","journal-title":"N Engl J Med"},{"key":"R42-2-20210130","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/00006982-200502000-00002","article-title":"Guidelines for using verteporfin (Visudyne) in photodynamic therapy for choroidal neovascularization due to age-related macular degeneration and other causes: update.","volume":"25","year":"2005","journal-title":"Retina"},{"key":"R43-2-20210130","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1136\/bjo.2007.134429","article-title":"Photodynamic therapy with verteporfin in paediatric and young adult patients: long-term treatment results of choroidal neovascularisations.","volume":"92","author":"Lipski","year":"2008","journal-title":"Br J Ophthalmol"},{"key":"R44-2-20210130","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1001\/archopht.126.7.941","article-title":"Bevacizumab treatment for subfoveal choroidal neovascularization from causes other than age-related macular degeneration.","volume":"126","author":"Chang","year":"2008","journal-title":"Arch Ophthalmol"},{"key":"R45-2-20210130","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1136\/bjo.2006.101337","article-title":"Intravitreal Avastin for choroidal neovascularisation in pathological myopia: the controversy continues.","volume":"91","author":"Rosenfeld","year":"2007","journal-title":"Br J Ophthalmol"},{"key":"R46-2-20210130","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1097\/01.iae.0000240121.28034.c3","article-title":"Treatment of choroidal neovascularization in pathologic myopia with intravitreal bevacizumab.","volume":"26","author":"Laud","year":"2006","journal-title":"Retina"},{"key":"R47-2-20210130","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1136\/bjo.2006.099887","article-title":"Intravitreal injection of bevacizumab for choroidal neovascularisation associated with pathological myopia.","volume":"91","author":"Sakaguchi","year":"2007","journal-title":"Br J Ophthalmol"},{"key":"R48-2-20210130","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1136\/bjo.2006.096776","article-title":"Intravitreal bevacizumab (Avastin) as treatment for subfoveal choroidal neovascularisation secondary to pathological myopia.","volume":"91","author":"Yamamoto","year":"2007","journal-title":"Br J Ophthalmol"},{"key":"R49-2-20210130","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1016\/j.ophtha.2007.03.043","article-title":"Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularization: six-month results of a prospective pilot study.","volume":"114","author":"Chan","year":"2007","journal-title":"Ophthalmology"},{"key":"R50-2-20210130","first-page":"707","article-title":"Short-term effects of intravitreal bevacizumab for subfoveal choroidal neovascularization in pathologic myopia.","volume":"27","author":"Hern\u00e1ndez-Rojas","year":"2007","journal-title":"Retina"},{"key":"R51-2-20210130","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s00347-008-1806-z","article-title":"Intravitreal Bevacizumab bei choroidaler Neovaskularisation infolge pathologischer Myopie.","volume":"106","author":"Dithmar","year":"2009","journal-title":"Ophthalmologe"},{"key":"R52-2-20210130","doi-asserted-by":"crossref","first-page":"182","DOI":"10.3928\/15428877-20080501-14","article-title":"Intravitreal bevacizumab for myopic choroidal neovascularization.","volume":"39","author":"Rensch","year":"2008","journal-title":"Ophthalmic Surg Lasers Imaging"},{"key":"R53-2-20210130","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ajo.2008.07.022","article-title":"Intravitreal bevacizumab treatment for choroidal neovascularization in pathologic myopia: 12-month results.","volume":"147","author":"Gharbiya","year":"2009","journal-title":"Am J Ophthalmol"},{"key":"R54-2-20210130","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1097\/IAE.0b013e31817eda41","article-title":"Short-term efficacy and safety of intravitreal ranibizumab for myopic choroidal neovascularization.","volume":"28","author":"Silva","year":"2008","journal-title":"Retina"},{"key":"R55-2-20210130","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1136\/bjo.2007.130260","article-title":"Intravitreal bevacizumab (Avastin) for choroidal neovascularisation secondary to pathological myopia: 6-month results.","volume":"92","author":"Arias","year":"2008","journal-title":"Br J Ophthalmol"},{"key":"R56-2-20210130","doi-asserted-by":"crossref","first-page":"576","DOI":"10.3129\/i08-104","article-title":"Intravitreal bevacizumab for the treatment of choroidal neovascularization associated with pathological myopia.","volume":"43","author":"Rh\u00e9aume","year":"2008","journal-title":"Can J Ophthalmol"},{"key":"R57-2-20210130","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ajo.2008.07.017","article-title":"Intravitreal bevacizumab for choroidal neovascularization attributable to pathological myopia: one-year results.","volume":"147","author":"Ikuno","year":"2009","journal-title":"Am J Ophthalmol"},{"key":"R58-2-20210130","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s00417-008-0995-0","article-title":"Intravitreal ranibizumab (Lucentis) for the treatment of myopic choroidal neovascularization.","volume":"247","author":"Konstantinidis","year":"2009","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R60-2-20210130","first-page":"50","article-title":"Marginal cracks after intravitreal bevacizumab for myopic choroidal neovascularization.","volume":"85","author":"Sayanagi","year":"2008","journal-title":"Acta Ophthalmol (Copenh)"},{"key":"R61-2-20210130","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s10792-007-9152-8","article-title":"Vitritis in the contralateral uninjected eye following intravitreal bevacizumab (Avastin).","volume":"28","author":"Neri","year":"2008","journal-title":"Int Ophthalmol"},{"key":"R62-2-20210130","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.ajo.2007.01.028","article-title":"An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration.","volume":"143","author":"Fung","year":"2007","journal-title":"Am J Ophthalmol"},{"key":"R63-2-20210130","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1034\/j.1600-0420.2002.800116.x","article-title":"Optical coherence tomography of choroidal neovascularization in high myopia.","volume":"80","author":"Baba","year":"2002","journal-title":"Acta Ophthalmol Scand"},{"key":"R64-2-20210130","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1136\/bjo.2007.135681","article-title":"Avastin in myopic choroidal neovascularisation: is age the limit?","volume":"92","author":"Wong","year":"2008","journal-title":"Br J Ophthalmol"},{"key":"R65-2-20210130","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.ajo.2004.05.074","article-title":"Photodynamic therapy of subfoveal choroidal neovascularization in high myopia in a clinical setting: visual outcome in relation to age at treatment.","volume":"138","author":"Axer-Siegel","year":"2004","journal-title":"Am J Ophthalmol"},{"key":"R66-2-20210130","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.ajo.2004.04.055","article-title":"Prognostic factors influencing visual outcome of photodynamic therapy for subfoveal choroidal neovascularization in pathologic myopia.","volume":"138","author":"Ergun","year":"2004","journal-title":"Am J Ophthalmol"},{"key":"R67-2-20210130","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.1600-0420.2006.00738.x","article-title":"Retinal pigment epithelium changes after photodynamic therapy for choroidal neovascularization in pathological myopia.","volume":"85","author":"Parodi","year":"2007","journal-title":"Acta Ophthalmol Scand"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00006982-200909000-00002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:06:29Z","timestamp":1786039589000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00006982-200909000-00002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9]]},"references-count":65,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0b013e3181b1bb1a","relation":{},"ISSN":["0275-004X"],"issn-type":[{"value":"0275-004X","type":"print"}],"subject":[],"published":{"date-parts":[[2009,9]]}}}